Related references
Note: Only part of the references are listed.Pirfenidone in idiopathic pulmonary fibrosis
H. Taniguchi et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Strategies for treating idiopathic pulmonary fibrosis
R. M. du Bois
NATURE REVIEWS DRUG DISCOVERY (2010)
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
C. M. Rubino et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2009)
Superoxide scavenging activity of pirfenidone-iron complex
Yoshihiro Mitani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
Hisashi Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Incidence and prevalence of idiopathic pulmonary fibrosis
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
High-dose acetylcysteine in idiopathic pulmonary fibrosis
M Demedts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis
T Kakugawa et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis
S Nagai et al.
INTERNAL MEDICINE (2002)
Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock
H Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats
S Tada et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2001)
Share Paper
